Bazedoxifene 10 mg/CE 0.625 mg + Bazedoxifene 20 mg/CE 0.625 mg + Bazedoxifene 40 mg/CE 0.625 mg + Bazedoxifene 10 mg/CE 0.45 mg + Bazedoxifene 20 mg/CE 0.45 mg + Bazedoxifene 40 mg/CE 0.45 mg + Raloxifene 60 mg + Placebo
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopause
Conditions
Postmenopause
Trial Timeline
May 1, 2009 → Aug 1, 2010
NCT ID
NCT00847821About Bazedoxifene 10 mg/CE 0.625 mg + Bazedoxifene 20 mg/CE 0.625 mg + Bazedoxifene 40 mg/CE 0.625 mg + Bazedoxifene 10 mg/CE 0.45 mg + Bazedoxifene 20 mg/CE 0.45 mg + Bazedoxifene 40 mg/CE 0.45 mg + Raloxifene 60 mg + Placebo
Bazedoxifene 10 mg/CE 0.625 mg + Bazedoxifene 20 mg/CE 0.625 mg + Bazedoxifene 40 mg/CE 0.625 mg + Bazedoxifene 10 mg/CE 0.45 mg + Bazedoxifene 20 mg/CE 0.45 mg + Bazedoxifene 40 mg/CE 0.45 mg + Raloxifene 60 mg + Placebo is a pre-clinical stage product being developed by Pfizer for Postmenopause. The current trial status is terminated. This product is registered under clinical trial identifier NCT00847821. Target conditions include Postmenopause.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00847821 | Pre-clinical | Terminated |
Competing Products
16 competing products in Postmenopause
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Comparator: placebo + Comparator: Estrace | Merck | Phase 1 | 33 |
| bazedoxifene/conjugated estrogens combination tablet | Pfizer | Phase 1 | 32 |
| Premarin | Pfizer | Pre-clinical | 22 |
| Bazedoxifene and conjugated estrogens | Pfizer | Phase 1 | 32 |
| Premarin/MPA + Premarin/MPA + Provera 10 mg | Pfizer | Phase 1 | 32 |
| Bazedoxifene/conjugated estrogens | Pfizer | Phase 1 | 32 |
| Premarin | Pfizer | Phase 1 | 32 |
| bazedoxifene BZA-20 | Pfizer | Phase 3 | 76 |
| Trimegestone + 17b Estradiol | Pfizer | Approved | 84 |
| Premarin/MPA 0.45 mg/1.5 mg | Pfizer | Phase 1 | 32 |
| Conjugated Estrogen Cream (Premarin®) | Pfizer | Pre-clinical | 22 |
| Estradiol/DRSP (Angeliq, BAY86-4891) | Bayer | Approved | 82 |
| 0.25mg DRSP / 0.5mg E2 (BAY86-4891) + 0.5mg NETA / 1.0mg E2 (Activella) | Bayer | Phase 3 | 74 |
| E2/LNG oral (Wellnara, BAY86-5029) | Bayer | Pre-clinical | 20 |
| Drospirenone/17ß-estradiol (Angeliq, BAY86-4891) + Drospirenone/17ß-estradiol (Angeliq, BAY86-4891) + SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM) | Bayer | Phase 2 | 49 |
| Tibolone + Estradiol + Estradiol + Medroxy Progesterone Acetate | Organon | Approved | 80 |